Han Kyu Lee

USPTO Granted Patents = 8 (Patent Applications = 5)

CIPO Patents = 3 (Patent Applications = 1)

EPO Patents = 4 (Patent Applications = 9)

Average Co-Inventor Count = 9.5

ph-index = 2

Forward Citations = 5(Granted Patents)

Location History:

Hwaseong-si, KR (2017 - 2020)
Gyeonggi-do, KR (2016 - 2024)

Company Filing History:

5 out of 7

Hyundai Pharm Co., Ltd.

Years Active: 2016-2025

Loading Chart...

8 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12421205 - GLP-1 receptor agonist (2025-09-23),

2. 11939334 - Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers (2024-03-26),

3. 11912710 - Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers (2024-02-27),

4. 10821110 - Composite preparation, containing novel 3-(4--(benzyloxy)phenyl)hex-4-inoic acid derivative and another active ingredient, for preventing or treating metabolic diseases (2020-11-03),

5. 10723699 - Cyclohexene derivative, preparation method thereof, and pharmaceutical composition for preventing or treating metabolic disease comprising the same as active ingredient (2020-07-28),

6. 9969723 - 3-(4-(benzyloxy)phenyl)hex-4-ynoic acid derivative, method of preparing same and pharmaceutical composition for preventing and treating metabolic disease including same as effective ingredient (2018-05-15),

7. 9758527 - Cyclohexene derivative, preparation method therefor, and pharmaceutical composition for preventing or treating metabolic diseases, containing same as active ingredient (2017-09-12),

8. 9508541 - Apparatus and method for treating substrate (2016-11-29),

Title: The Innovations of Han Kyu Lee

Introduction

Han Kyu Lee is a prominent inventor based in Gyeonggi-do, South Korea. He has made significant contributions to the field of pharmaceuticals, holding a total of eight patents. His work focuses on developing compounds that have the potential to treat various diseases.

Latest Patents

One of his latest patents is a GLP-1 receptor agonist. This invention relates to a compound represented by Formula 1, which serves as a GLP-1 receptor agonist and may be useful in the prevention or treatment of diseases associated with GLP-1 activity. Another notable patent involves substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers. This disclosure relates to a novel PLK1 degradation-inducing compound, which exhibits an effect of inducing PLK1 degradation and may be effectively utilized for preventing or treating PLK1-related diseases.

Career Highlights

Throughout his career, Han Kyu Lee has worked with notable companies such as Hyundai Pharm Co., Ltd. and Uppthera. His experience in these organizations has allowed him to develop and refine his innovative ideas in the pharmaceutical industry.

Collaborations

Some of his coworkers include Jin Wook Yang and Jae Hyun Kim. Their collaboration has contributed to the advancement of research and development in their respective fields.

Conclusion

Han Kyu Lee's contributions to the pharmaceutical industry through his patents and collaborations highlight his role as an influential inventor. His work continues to pave the way for advancements in medical treatments.

This text is generated by artificial intelligence and may not be accurate.